An explanation of the positive role of Nanofenretinide on naxitamab effect can be found in the inhibition of the PI3K/AKT/mTOR pathway that has been demonstrated for both fenretinide [39] and anti-GD2 mAbs [7] in NB cells. The gene discussed is MTOR; the disease is neuroblastoma.